Abstract
SummaryPatients that are being treated for different types of malignancies may develop eye problems, which may be due to their treatment. We studied patients that received treatment with the MEK inhibitor binimetinib prospectively: 23% of 30 patients with metastatic cutaneous melanoma and 5 patients with metastatic uveal melanoma reported visual complaints during treatment. These complaints were time‐dependent, mild, and reversible. OCT revealed serous subretinal fluid in 74% of patients. Moreover, a persistent profoundly abnormal electro‐oculogram was found, indicating a panretinal dysfunction of the retinal pigment epithelium. Since no other abnormalities could be detected on multimodal imaging, this clinical entity is referred to as MEK‐associated serous retinopathy.Ophthalmological monitoring is warranted in patients using MEK inhibitors; however, discontinuation of administration generally does not seem necessary because of the relatively low visual impact and transient nature of the associated serous retinopathy. Possible pathogenetic mechanisms of this retinopathy include anti‐RPE and anti‐retinal autoantibodies and/or direct RPE toxicity of MEK inhibitors.Ophthalmology. 2015 Sep;122(9):1907‐16. https://doi.org/10.1016/j.ophtha.2015.05.027
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
